861 related articles for article (PubMed ID: 9067765)
1. The augmenting effect of OK432-stimulated B cells on the in vitro generation of anti-tumor cytotoxic T lymphocytes from tumor-draining lymph node cells: the possible role of interleukin-12.
Shinomiya Y; Harada M; Tamada K; Kurosawa S; Okamoto T; Terao H; Takenoyama M; Ito O; Hirashima C; Li T; Shirakusa T; Nomoto K
In Vivo; 1997; 11(1):1-8. PubMed ID: 9067765
[TBL] [Abstract][Full Text] [Related]
2. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
3. Local injection of OK432 can augment the TH1-type T-cell response in tumor-draining lymph node cells and increase their immunotherapeutical potential.
Okamoto T; Harada M; Tamada K; Yoshida H; Ito O; Kong YY; Takenoyama M; Hirashima C; Matsuzaki G; Nomoto K
Int J Cancer; 1997 Mar; 70(5):598-605. PubMed ID: 9052762
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice.
Lynch DH; Miller RE
Eur J Immunol; 1991 Jun; 21(6):1403-10. PubMed ID: 1904359
[TBL] [Abstract][Full Text] [Related]
5. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
Matsumura T; Krinock RA; Chang AE; Shu S
Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
[TBL] [Abstract][Full Text] [Related]
6. Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.
Kurosawa S; Harada M; Matsuzaki G; Shinomiya Y; Terao H; Kobayashi N; Nomoto K
Immunology; 1995 Jun; 85(2):338-46. PubMed ID: 7642226
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
Arca MJ; Krauss JC; Aruga A; Cameron MJ; Shu S; Chang AE
Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
Li Q; Carr AL; Donald EJ; Skitzki JJ; Okuyama R; Stoolman LM; Chang AE
Cancer Res; 2005 Feb; 65(3):1063-70. PubMed ID: 15705908
[TBL] [Abstract][Full Text] [Related]
9. CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells.
Ponzio NM; Cutro S; Hu J; Marzouk A; Marshall JD
Int Immunopharmacol; 2006 Dec; 6(13-14):2057-68. PubMed ID: 17161362
[TBL] [Abstract][Full Text] [Related]
10. Dissociation of severe lupus-like disease from polyclonal B cell activation and IL 2 deficiency in C3H-lpr/lpr mice.
Davidson WF; Roths JB; Holmes KL; Rudikoff E; Morse HC
J Immunol; 1984 Aug; 133(2):1048-56. PubMed ID: 6610701
[TBL] [Abstract][Full Text] [Related]
11. The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells.
Dye ES
J Immunol; 1986 Feb; 136(4):1510-5. PubMed ID: 3080526
[TBL] [Abstract][Full Text] [Related]
12. Potential involvement of monocyte chemoattractant protein (MCP)-1/CCL2 in IL-4-mediated tumor immunity through inducing dendritic cell migration into the draining lymph nodes.
Wang H; Nemoto-Sasaki Y; Kondo T; Akiyama M; Mukaida N
Int Immunopharmacol; 2003 May; 3(5):627-42. PubMed ID: 12757733
[TBL] [Abstract][Full Text] [Related]
13. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
Li T; Harada M; Tamada K; Abe K; Nomoto K
Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
[TBL] [Abstract][Full Text] [Related]
14. T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes.
Ron Y; Sprent J
J Immunol; 1987 May; 138(9):2848-56. PubMed ID: 2952725
[TBL] [Abstract][Full Text] [Related]
15. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
16. Role of the endogenous production of interleukin 12 in immunotherapy.
Harada M; Tamada K; Abe K; Yasumoto K; Kimura G; Nomoto K
Cancer Res; 1998 Jul; 58(14):3073-7. PubMed ID: 9679973
[TBL] [Abstract][Full Text] [Related]
17. The B cell is the initiating antigen-presenting cell in peripheral lymph nodes.
Janeway CA; Ron J; Katz ME
J Immunol; 1987 Feb; 138(4):1051-5. PubMed ID: 3100626
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes.
Lynch DH; Namen AE; Miller RE
Eur J Immunol; 1991 Dec; 21(12):2977-85. PubMed ID: 1684156
[TBL] [Abstract][Full Text] [Related]
19. In vivo regulation of the cytolytic T cell response to hapten-altered self: suppressor T cells induced in the regional lymph nodes by exposure to syngeneic spleen cells.
Wong HL; Battisto JR
Eur J Immunol; 1984 Jul; 14(7):629-33. PubMed ID: 6235115
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.
Ko BK; Efferson CL; Kawano K; Kuerer HM; Sahin A; Murray JL; Ioannides CG
Int J Oncol; 2004 Jun; 24(6):1413-8. PubMed ID: 15138582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]